Feb 1, 2026 – The global medical device industry is experiencing steady and robust growth amid technological integration and evolving market demands, with emerging innovations and the rising influence of domestic manufacturers reshaping the sector’s landscape, according to recent industry reports and regulatory updates.
The global market size of medical devices is projected to exceed $680 billion in 2025, maintaining a compound annual growth rate (CAGR) of over 5.5%, driven by aging populations, surging prevalence of chronic diseases, and the rapid integration of digital health technologies worldwide. Asia has emerged as a key growth engine, contributing more than 40% of the global growth, with China’s domestic innovation capacity and manufacturing advantages redefining the global supply chain structure.
Technological innovation remains the core driver of industry development. Artificial intelligence (AI)-enabled medical device software is expected to reach a market size of $32 billion in 2025, a 28% increase from the previous year, while the installed base of remote patient monitoring devices has surpassed 120 million units globally. Minimally invasive surgical robot systems have achieved a 35% penetration rate in global surgical centers, and the integration of gene editing technology with diagnostic equipment has spawned a new generation of precision medical solutions, redefining the industry’s value chain.
In China, the domestic medical device sector has made remarkable breakthroughs. In 2025, China’s National Medical Products Administration (NMPA) approved 76 domestic innovative medical devices, marking three consecutive years of high-volume approvals, covering cardiovascular, oncology, ophthalmology, and neurological fields. Domestic enterprises have shifted from imitation to original innovation, with their market share approaching 45%, breaking the monopoly of foreign brands in high-end segments. For instance, United Imaging launched the world’s first dual-wide-body dual-source CT and China’s first photon-counting spectral CT, while MicroPort’s interventional devices have gained recognition in global clinical applications.
Policy support and regulatory optimization have laid a solid foundation for industry development. As of September 2025, 17 major global markets have updated their medical device regulatory frameworks, and digital therapy approval channels have been established in 12 countries. In China, the NMPA has optimized review and approval processes, opening green channels for innovative medical devices to shorten the R&D-to-market cycle. Meanwhile, the update of 139 national and industrial standards in 2025, including the first national standard for brain-computer interface medical devices, has standardized industry innovation.
The industry’s competitive landscape is also evolving. While the top 20 global medical device enterprises hold 65% of the market share, innovative enterprises in niche segments are gaining traction